INGAP Peptide

Drug Profile

INGAP Peptide

Alternative Names: Exsulin; INGAP-Peptide

Latest Information Update: 21 Dec 2015

Price : $50

At a glance

  • Originator Eastern Virginia Medical School; McGill University
  • Developer Exsulin Corporation; Jewish General Hospital
  • Class Cytokines; Peptide fragments
  • Mechanism of Action Transcription factor stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 29 Apr 2016 Biomarkers information updated
  • 06 Aug 2015 Phase-II development for Type 2 diabetes mellitus and Type 1 diabetes mellitus is ongoing in USA and Canada
  • 01 Feb 2014 Exsulin terminates a phase II trial in Type-1 diabetes mellitus in the US and Canada (NCT00995540)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top